Literature DB >> 34039482

Management of bacterial and fungal infections in cirrhosis: The MDRO challenge.

Javier Fernández1, Salvatore Piano2, Michele Bartoletti3, Emmanuel Q Wey4.   

Abstract

Bacterial infections are frequent in cirrhotic patients with acute decompensation or acute-on-chronic liver failure and can complicate the clinical course. Delayed diagnosis and inappropriate empirical treatments are associated with poor prognosis and increased mortality. Fungal infections are much less frequent, usually nosocomial and associated with extremely high short-term mortality. Early diagnosis and adequate empirical treatment of infections is therefore key in the management of these patients. In recent decades, antibiotic resistance has become a major worldwide problem in patients with cirrhosis, warranting a more complex approach to antibiotic treatment that includes the use of broad-spectrum antibiotics, new administration strategies, novel drugs and de-escalation policies. Herein, we review epidemiological changes, the main types of multidrug-resistant organisms, mechanisms of resistance, new rapid diagnostic tools and currently available therapeutic options for bacterial and fungal infections in cirrhosis.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; Antibiotic strategies; Epidemiology; Prevalence; Prognosis

Mesh:

Substances:

Year:  2021        PMID: 34039482     DOI: 10.1016/j.jhep.2020.11.010

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

Review 1.  Roles for the mycobiome in liver disease.

Authors:  Suling Zeng; Bernd Schnabl
Journal:  Liver Int       Date:  2022-01-17       Impact factor: 5.828

Review 2.  Promises of microbiome-based therapies.

Authors:  Jasmohan S Bajaj; Siew C Ng; Bernd Schnabl
Journal:  J Hepatol       Date:  2022-06       Impact factor: 30.083

Review 3.  Liver Transplantation as a Cornerstone Treatment for Acute-On-Chronic Liver Failure.

Authors:  Martin S Schulz; Wenyi Gu; Andreas A Schnitzbauer; Jonel Trebicka
Journal:  Transpl Int       Date:  2022-03-17       Impact factor: 3.842

4.  New concepts and perspectives in decompensated cirrhosis.

Authors:  Rajiv Jalan; Gyongyi Szabo
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

Review 5.  Prevalence and Therapeutic Management of Infections by Multi-Drug-Resistant Organisms (MDROs) in Patients with Liver Cirrhosis: A Narrative Review.

Authors:  Lorenzo Onorato; Caterina Monari; Salvatore Capuano; Pierantonio Grimaldi; Nicola Coppola
Journal:  Antibiotics (Basel)       Date:  2022-02-11

6.  Abundance of Lipopolysaccharide Heptosyltransferase I in Human Gut Microbiome and Its Association With Cardiovascular Disease and Liver Cirrhosis.

Authors:  Shujin Lin; Hui Zhang; Xueke Wang; Ting Lin; Zihan Chen; Jingfeng Liu; Jianmin Wang
Journal:  Front Microbiol       Date:  2021-11-30       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.